Table 2.
Patient characteristics of the retrospective cohorts with long-term survival and complications.
| ALD (n = 182) | HCV (n = 267) | p value⁎ | |
|---|---|---|---|
| Age (years) | 57.2 ± 9.2 | 56.3 ± 12.0 | 0.396 |
| Gender (% male) | 77.5% | 74.1% | 0.193 |
| AST (U/L) | 39 (34-79) | 71 (36-105) | ≪0.001 |
| ALT (U/L) | 34 (21-53) | 45 (22-71) | 0.008 |
| Bilirubin (mg/dl) | 1.4 (0.8-2.1) | 0.7 (0.4-1.2) | ≪0.001 |
| Platelets (103/μl) | 155 ± 80 | 95 ± 70 | ≪0.001 |
| Albumin (mg/dl) | 3.69 ± 0.43 | 3.81 ± 0.62 | 0.023 |
| INR | 1.09 ± 0.19 | 1.09 ± 0.26 | 0.989 |
| Creatinine (mg/dl) | 0.89 ± 0.78 | 0.78 ± 0.38 | ≪0.001 |
| Liver size (cm) | 16.8 ± 3.2 | 13.5 ± 2.2 | ≪0.001 |
| Spleen size (cm) | 12.5 ± 2.8 | 17.5 ± 4.2 | ≪0.001 |
| Liver stiffness (kPa) | 32.7 ± 19.7 | 20.1 ± 11.3 | ≪0.001 |
| SL/LS ratio | 0.62 ± 0.55 | 1.15 ± 0.67 | ≪0.001 |
| Mortality | 43 (23.6%) | 64 (23.9%) | |
| Decompensation | 118 (64.8%) | 153 (57.5%) | |
| Mode of first decompensation | |||
| Jaundice | 77 (65.3%) | 6 (3.9%) | ≪0.001 |
| Variceal bleeding | 11 (9.3%) | 112 (73.2%) | ≪0.001 |
| Ascites | 26 (22%) | 32 (20.9%) | 0.739 |
| Encephalopathy | 4 (3.4%) | 3 (2.0%) | 0.329 |
| Incidence of decompensation modes within mortality cohort (over lifetime) | |||
| Jaundice | 40 (93%) | 18 (28%) | ≪0.001 |
| Variceal bleeding | 7 (16.2%) | 61 (95.3%) | ≪0.01 |
| Ascites | 31 (72.1%) | 45 (70.3%) | 0.78 |
| Encephalopathy | 29 (67.4%) | 46 (72%) | 0.34 |
ALD, alcohol-related liver disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HCV, hepatitis C virus; INR, international normalized ratio; LS, liver stiffness; SL, spleen length.
*
The statistical test used is unpaired t test.